Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05631574
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:52.721851+00:00
Published At
2025-02-07T00:00:00+00:00
Record Updated At
2025-02-07
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Non Small Cell Lung Cancer", "Pancreatic Cancer", "Colorectal Cancer", "NSCLC", "PDAC", "CRC", "Relapsed Cancer", "Refractory Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer", "Stage III Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage III Colorectal Cancer", "Stage IV Colorectal Cancer", "Stage III NSCLC", "Stage IV NSCLC", "KRAS Mutation-Related Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-02-07"
protocolSection.identificationModule.nctId
"NCT05631574"
protocolSection.identificationModule.officialTitle
"A Phase 1/1b Dose Finding Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Unresectable, Locally Advanced, or Metastatic Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer (PDAC), and Colorectal Cancer (CRC)"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • NSCLC (protocolSection.conditionsModule.conditions)
  • PDAC (protocolSection.conditionsModule.conditions)
  • CRC (protocolSection.conditionsModule.conditions)
  • Relapsed Cancer (protocolSection.conditionsModule.conditions)
  • Refractory Cancer (protocolSection.conditionsModule.conditions)
  • Stage III Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Pancreatic Cancer (protocolSection.conditionsModule.conditions)
  • Stage III Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Stage III Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Colorectal Cancer (protocolSection.conditionsModule.conditions)
  • Stage III NSCLC (protocolSection.conditionsModule.conditions)
  • Stage IV NSCLC (protocolSection.conditionsModule.conditions)
  • KRAS Mutation-Related Tumors (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.